Latest news with #BrukerCorporation
Yahoo
3 days ago
- Business
- Yahoo
Bruker Corporation to Present at the Jefferies Global Healthcare Conference
BILLERICA, Mass., May 30, 2025--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will participate in the Jefferies Global Healthcare Conference in New York City with a fireside chat presentation scheduled for Wednesday, June 4th, 2025 at 5:30 PM Eastern Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at A replay of the presentation will be posted in the "Events & Presentations" section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit View source version on Contacts Joe KostkaDirector, Investor RelationsBruker CorporationT: +1 (978) 313-5800E: Sign in to access your portfolio
Business Wire
3 days ago
- Business
- Business Wire
Bruker Corporation to Present at the Jefferies Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will participate in the Jefferies Global Healthcare Conference in New York City with a fireside chat presentation scheduled for Wednesday, June 4 th, 2025 at 5:30 PM Eastern Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at A replay of the presentation will be posted in the 'Events & Presentations' section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit
Business Wire
3 days ago
- Business
- Business Wire
Bruker Launches Revolutionary timsOmni TM Mass Spectrometer
BALTIMORE--(BUSINESS WIRE)--For the 73 rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) announced the launch of the timsOmni™ system, a transformative new timsTOF-based mass spectrometer designed for scientific, drug discovery, and clinical researchers, as well as for advanced QC on biologics, offering deep structural insights into the functional or pathological proteoforms or oligonucleotides. Multimodal eXd trapping with precise electron energy control, ion accumulation, and reaction time regulation is a cornerstone innovation of the timsOmni™ platform. This also enables CIU, further expanding the value of proteoform CCS information, followed by multiple electron-based (ECD, EID) and collision-based (CID) fragmentation techniques. The timsOmni uniquely enables protein researchers and biologics developers to tailor information-rich dissociation pathways for deeper insights - with high speed and high sensitivity. The 'Swiss-army knife' type flexibility of the timsOmni top-down capability enables the identification of low-abundant, aberrant proteoforms, the structurally altered versions of proteins arising from genetic mutations, alternative splicing, or post-translational modifications that deviate from normal physiological forms, disrupting protein function, misfolding, or aggregation, and often play critical roles in the onset and progression of human diseases, including cancer, neurodegeneration, cardiovascular disorders, and autoimmune conditions. Anders Giessing, PhD, Science Manager at Novonesis in Denmark, said, 'We use intact protein mass analysis to ensure performance, stability, and consistency of our diverse protein product portfolio. Introduction of the timsOmni, with its Swiss Army knife versatility, redefines intact mass and top-down analysis with the precision, speed, and confidence needed to provide definitive analytical support in the development and production of industrial enzymes.' The Omnitrap's signature high-sensitivity, high-speed, multimodal eXd capability is particularly powerful for mapping PTMs, such as histone proteoforms (H3:1K14ac) that play a crucial role in regulating gene expression by altering chromatin structure and controlling access to the DNA. Other PTMs like glycosylation critically influence protein folding, stability, transport, and cell signaling interactions, and detailed top-down or middle-down sequencing of complementarity-determining regions (CDRs) in humoral and therapeutic antibodies are important in cancer, autoimmunity and biologics development. Prof. Albert Heck, Professor of Chemistry and Pharmaceutical Sciences at Utrecht University and Scientific Director of the Netherlands Proteomics Center, commented, 'Proteomics will finally go 'protein-centric' by using the timsOmni. The multimodal eXd capability allows for comprehensive ion sequence ladders that are ideal for de novo sequencing and human plasma antibody repertoire profiling. Analyzing and monitoring circulating antibody levels is critical for characterizing the progression of a disease, identifying patients with delayed symptom onset, and predicting potential long-term immunity.' Frank H. Laukien, Ph.D., the CEO of Bruker Corporation, added, 'The timsOmni is a new lamppost for functional protein science, shining a light on functional and pathological proteoforms and truly enabling a new protein science paradigm for fundamental cell and molecular biology, signal transduction, cancer, neurodegeneration, and other disease research. The timsOmni will also be extremely valuable for biopharma drug discovery and development, as well as for biologics QC analysis, from therapeutic antibodies to antibody-drug conjugates.' The timsOmni is supported by OmniScape™, Bruker's next-generation top-down proteomics software that features state-of-the-art algorithms for de-isotoping complex spectra, automated charge state assignment, de novo protein sequencing support, and sequence confirmation. These key features provide unrivaled benefits for the accurate identification of proteoforms, post-translational modifications, and non-canonical proteins. OmniScape transforms complex eXd fragmentation spectra into actionable biological insights—empowering researchers to navigate the new world of functional proteoformics. Prof. Ole N. Jensen, Group Leader at the Protein Research Group of the University of Southern Denmark, observed, 'The timsOmni technology and OmniScape software already impacted our strategies for intact protein and proteoform analysis. Multimodal MS/MS fragmentation and MS3 afford very high amino acid sequence coverage and accurate localization of post-translational modifications in histones.' The timsOmni comes with the new NEOS off-line nanoESI for the extremely low infusion flow rates required for the study of protein complexes, allowing for extended analysis of scarce samples. The NEOS source works with coated and non-coated emitters. Additionally, the timsOmni retains the high sensitivity of the timsTOF Ultra 2 for nLC dia-PASEF high-throughput bottom-up 4D-proteomics. The timsOmni ushers in a new era of functional proteomics, setting the stage for landmark discoveries in ' Proteoformics ', and advancing a transformative new paradigm in protein research as it illuminates protein function through the deep sequencing of proteoforms, humoral and multi-specific antibodies, and other complex biomolecules. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit
Business Wire
3 days ago
- Business
- Business Wire
Bruker Launches Novel timsMetabo ™ Mass Spectrometer for Breakthrough 4D-Metabolomics and 4D-Lipidomics Sensitivity, Specificity and Annotation Confidence - at Speed, Depth, and Scale
BALTIMORE--(BUSINESS WIRE)--At the 73 rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) launched timsMetabo, a peak-performance 4D-Metabolomics™ mass spectrometer delivering unprecedented sensitivity, separation power and annotation confidence for small molecules, further enhanced by the novel TIMS 'MoRE' scan-mode. The timsMetabo system enables the generation of a 'digital metabolome archive' for every sample, providing TIMS-enabled qual-quant performance with greatly increased confidence for automated annotation, leveraging 4D separations and reproducible molecular collision cross sections (CCS) at scale for 4D-Metabolomics and 4D-Lipidomics™. Breakthrough timsMetabo Performance with MoRE The benchtop timsMetabo system combines unique and powerful trappped ion mobility separation (TIMS) technology and time-focussing for exceptional sensitivity. Novel Mobility Range Enhancement (MoRE) acquisition leverages the enhanced ion capacity of the dual-stage TIMS-MX ion funnel, expanding its mass-to-charge and mobility ranges. Coupled with a new high-precision quadrupole and the innovative Athena Ion Processor (AIP), the timsMetabo is the next-generation 4D-Metabolomics research and validation workhorse for unprecedented confidence in small molecule analysis in complex mixtures – with sensitivity at speed and scale. The timsMetabo excels at resolving isomers, isobars, and interferences in routine operation owing to its unique additional real-time gas phase CCS ion separation capability, delivering highly-selective MS1-based quantification – at speed and scale. For assays requiring precision at the limit of quantitation, the AIP-equipped timsMetabo provides cleaner, less-chimeric MS/MS acquisition at rates up to 300 Hz for targeted quantitative analysis using parallel reaction monitoring. The AIP leverages mobility information encoded by TIMS in each acquisition cycle for optimal transfer of MS and MS/MS-derived ions for TOF mass analysis. These novel features synergistically produce a rich digital metabolome archive of metabolite identity and quantity from each sample, enabling confident analysis, and enabling AI in metabolomics with machine learning from large-scale, high-quality data sets. The timsMetabo supports both HESI and CSI ion sources for coupling with analytical flow, microflow and nanoflow high-performance liquid chromatography. Dr. Frédéric Vaz, Associate Professor and Head of the Core Facility Metabolomics (CFM) at University of Amsterdam Medical Center, said: 'The timsMetabo uniquely combines sensitivity and selectivity, facilitating measurement of both, known biomarkers and the exploration of new metabolic signatures in research on inborn errors of metabolism. This performance versatility in a single instrument accelerates our research in expanding our knowledge of human metabolism from a clinical/translational perspective towards our ultimate goal to use such technologies to unravel pathologic mechanism of disease and promote new therapeutic strategies for both inherited and acquired disorders.' Prof. Pieter Dorrestein, Professor at the University of San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, Director, Collaborative Mass Spectrometry Innovation Center and Co-Director, Institute for Metabolomics Medicine, commented: ' Bile acids are a diverse and biologically important class of molecules involved in nutrient transport, immune regulation, and are altered in response to medications, diet, and disease. Thousands of distinct bile acid structures – including newly discovered microbially modified forms – are now being revealed. Ion mobility, enhanced by reproducible CCS values at scale, alongside chromatography and MS/MS, is unlocking this hidden complexity, advancing our understanding of bile acid biology, clinical research, and therapeutic discovery. The technology within the timsMetabo will help us better understand this biologically diverse class of molecules routinely, at speed and scale, and this is an exciting combination.' QSee™ quality control suite by Bruker Bruker also launches the QSee quality control (QC) suite of software and reference materials for automated evaluation of instrument performance and long-term monitoring via cloud-based TwinScape™ software. In partnership with Polymer Factory Sweden AB, the leading manufacturer of stable polymer-based mass spectrometry calibrants, the SpheriCal® platform has been extended to include the new QSee 8-mix for assessment of chromatographic and mass spectrometry performance. Results are archived for comparison across time using the TwinScape cloud-based solution already available for proteomics. Dr. Christoph Trautwein, Director of the Core Facility Metabolomics at University of Tübingen, commented: 'By integrating QSee Performance Testing into our lab routine, we're conveniently benchmarking our LC-TIMS-MS system performance before each experiment. The slim and intuitive workflow makes this a straightforward check, and the results provide assurance and 'peace of mind' that we're consistently producing high quality quantitative data. Confidence in our analytical results has never been higher, thanks to this comprehensive solution. It's truly a QC game-changer for our metabolomics lab.' Additionally, TASQ®'s RealTimeQC capabilities for within-batch data quality monitoring have been enhanced with improved data visualization including LC system pressure. Professor Thomas Moritz of the Novo Nordisk Foundation Centre for Basic Metabolic Research at the University of Copenhagen, added: 'Bruker's commitment to making data quality information immediately accessible is evident with TASQ RealTimeQC. Their innovative solution to quality monitoring provides assurance when it matters most and helps us make informed decision during the analysis, before it's too late to act. With RealTimeQC, Bruker is uniquely and directly supporting lab-based metabolomics and lipidomics research." Dr. Matthew Lewis, VP Metabolomics and Lipidomics at Bruker, concluded: 'The novel timsMetabo represents a step-change in 4D-Metabolomics and 4D-Lipidomics, and a sustained commitment to innovation in these application spaces. With an unrelenting focus, we are elevating our customer's hands-on experience by listening to their needs and delivering unique features in data analysis, confidence in automated metabolite annotation, and informed quality monitoring.' About Bruker Corporation (Nasdaq: BRKR) Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visit
Business Wire
5 days ago
- Business
- Business Wire
Bruker Introduces Novel MOVE-T System for Transferable, Robust Milk and Liquid Dairy Analysis with FT-NIR Technology
ETTLINGEN, Germany--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced the launch of the MOVE-T, a state-of-the-art liquid dairy analyzer designed to elevate quality control standards in the dairy industry. Utilizing advanced Fourier Transform Near-Infrared (FT-NIR) technology, the MOVE-T provides unparalleled precision analyzing raw milk and other liquid dairy products, ensuring superior product quality and consistency. Tailored for the dairy industry and sectors processing liquid dairy products or plant-based drinks, it provides a robust tool for enhancing product quality and operational efficiency. The integration of FT-NIR technology with a wear-free quartz cell ensures high sensitivity, specificity, and transferability, making the MOVE-T an indispensable asset for modern dairy quality control. By leveraging the superior stability of FT-NIR technology over time and across instruments, the analyzer delivers precise and reliable results in accordance with ISO 21543 (IDF 201), setting a new benchmark in liquid dairy analysis and empowering producers to maintain consistent product quality. Katharina Baumgartner, Dairy Laboratory Specialist and long-time user of FT-NIR technology for milk analysis instruments at GOLDSTEIG Cheese Factories Bayerwald GmbH, commented: "We are thrilled with the new MOVE-T. The compact and integrated design seamlessly fits into our workflow. The transferability of methods is exceptionally good, as are the results for our key products in quality control. We are very excited about the market launch of the MOVE-T." Dr. Jörg-Peter Conzen, Vice-President of Bruker Optics, added, "The MOVE-T reflects our dedication and our commitment to innovation and analytical excellence. By providing the dairy industry with cutting-edge NIR technology, we are helping our customers achieve greater efficiency and product consistency. This launch completes our proven portfolio of dairy FT-NIR analyzers for lab and process control." About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nano analysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit
